In this study, we have investigated the therapeutic potential of the PLK1 inhibitor onvansertib in combination with the FDA-approved PI3Kα inhibitor alpelisib for advanced HR+ breast cancer. This evidence concerns the gene PLK1 and breast carcinoma.